The Use of Solid Phase Reactors as the Source of a Catalytic Solution. The Indirect Flow-Injection Spectrophotometric Determination of Amino Acids

I. Gil Torró, J.V. García Mateo, and J. Martínez Calatayud

Departamento de Química Analítica, Universidad de Valencia, Moliner 50, Burjasot, 46100 Valencia, Spain

bDepartamento de Química, Colegio Universitario CEU, Moncada, Valencia, Spain

Received: February 27, 1996; August 12, 1996

A determinação indiretada aminoácidos é realizada em um sistema de injeção de fluxo utilizando-se um reator de fase sólida que contém sais cúpricos, imobilizados em esferas de resina de poliéster. Uma substância farmacêutica é forçada através do reator e os íons cúpricos liberados (complexados pela substância farmacêutica) agem como catalisadores da reação subsequente entre Fe(III) e tirosulfato de sódio. A curva de calibração é linear no intervalo de concentrações 0,1-0,3 µg L⁻¹ para glicina, com um desvio padrão relativo de 2,3% e uma velocidade de passagem de 28 amostras por hora. Foi analisada a influência de substâncias estranhas e o método foi aplicado à determinação de glicina em duas formulações farmacêuticas diferentes.

The indirect determination of amino acids is carried out in a flow-injection assembly by means of a solid-phase reactor containing cupric salts, immobilized in polyester resin beads. A pharmaceutical substance is forced through the reactor and the released cupric ions (complexed by the pharmaceutical substance) act as a catalyst for the subsequent reaction between Fe(III) and sodium thiosulfate. The calibration graph is linear over the range 0.1-3.0 µg mL⁻¹ glycine, the RSD was 2.3%, and the sample throughput was 28 h⁻¹. The influence of foreign substances was studied and the method was applied to the determination of glycine in two different pharmaceutical formulations.

Keywords: Cu(II) catalyst, spectrophotometry, glycine, amino acids, flow analysis, solid-phase reactors

Introduction

Solid phase reactors are now firmly established in continuous-flow applications. Their use in FI assemblies offers some advantages over the homogeneous solution systems that have been illustrated in several papers¹,²,³. In fact, FI solid phase reactors afford a variety of applications and facilitate sample derivation. So far they have been used for the purification of both sample and reagent solutions, and for the in situ preparation of unstable reagents⁴.

Several methods have been proposed for the determination of amino acids as relevant indicators of nutritional requirements. The direct titrimetric determination of amino acids in multivitamin formulations has been officially recommended⁵. However, most of the published methods for the determination of amino acids are based on the derivation of the analyte, which allows an increase in sensitivity and facilitates the separation step in real samples, which usually contain a mixture of several amino acids. In this way, fluorimetric⁶, polarographic⁷, and chromatographic methods (TLC⁸, GC⁹,¹⁰ and HPLC¹¹-¹³) have been proposed.

Some methods based on the FI methodology have been developed. Glycine and cysteine can be fluorimetrically determined by means of prior oxidation with potassium
iodate in the presence of 2-mercaptoethanol\textsuperscript{14}. Indirect determinations of amino acids in pharmaceutical formulations have been carried out using solid-phase reactors\textsuperscript{15,16} and atomic absorption for the detection of the metallic cation liberated from the reactor. Sensors for industrial process monitoring using enzyme-cartridge flow-injection analysis\textsuperscript{17,18}, electrodialysis with amino acid oxidation to enhance selectivity in FI for L-amino acids\textsuperscript{19}, and biocatalytic sensors based on electrically wired peroxidase\textsuperscript{20}, have improved the analytical strategies for amino acids.

This paper deals with a new strategy for exploiting the use of solid phase reactors for the indirect determination of pharmaceutical substances. The proposed manifold includes a reactor containing copper carbonate immobilized on a polymer resin. On passage through the reactor, the sample forms a complex and releases the metal ion; then the released cupric ion acts as the catalyst in a subsequent reaction between Fe(III) and thiosulfate ion. The product of this reaction (ferrous ion) is spectrophotometrically monitored (at 510 nm) by reaction with 1,10-phenanthroline (hence forth referred to as phen).

**Experimental**

**Reagents**

Aqueous solutions of glycine (Probus) at pH 9.5 were potentiometrically adjusted by dripping diluted NaOH (Panreac). The other aqueous solutions were ferric nitrate (Panreac), sodium thiosulfate (Panreac), phen in 0.05 mol L\textsuperscript{-1} HCl (Panreac). The solid-phase reactor was prepared according to a previously published procedure\textsuperscript{15} with CuCO\textsubscript{3}, Cu(OH)\textsubscript{2}, 2H\textsubscript{2}O (Panreac), polyester resin solution AL-100-A (Reposa) containing the cobalt activator and adding methylketone (Akzo) as the catalyst. All reagents used were of analytical grade, unless otherwise stated.

**Apparatus**

The proposed FIA manifold is depicted in Fig. 1. The assembly was provided with a Minipuls 2 peristaltic pump (Gilson) and a 5041 injecting valve (Rheodyne). The complex formed was monitored at 510 nm by a Lambda 16 (Perkin-Elmer) spectrophotometer, provided with a 18 µl flow-cell (Hellma). The PTFE tubes were of 0.8 mm ID, except the solid-phase reactor which was prepared with 1.5 mm ID PTFE tubes.

**Procedures**

578 µL of aqueous alkaline glycine solution at pH 9.5 (potentiometrically adjusted by dripping diluted NaOH) was injected into the carrier solution of NaOH (pH 9.5, flow-rate 2.6 mL min\textsuperscript{-1}). The injected solution was forced through the solid-phase reactor (10 cm long, 1.5 mm ID, and particle size 150-200 µm), and then merged with a 7.0 x 10\textsuperscript{-4} mol L\textsuperscript{-1} Fe(III) solution. The subsequent mixture with a 2.58 x 10\textsuperscript{-3} mol L\textsuperscript{-1} Na\textsubscript{2}S\textsubscript{2}O\textsubscript{3} solution produced Fe(II), which was spectrophotometrically determined at 510 nm by means of reaction with a 0.5% (w/v) phen solution.

**Results and Discussion**

Figure 2 shows the experimental setup and solutions used in preliminary experiments with a number of pharmaceutical substances that released cupric ion from the reactor by a displacement reaction. The cupric ion, released from the solid-phase reactor by complexation with the pharmaceutical substance, acts as a catalyst for the reaction between Fe(III) and thiosulfate ion. The injection of a phen solution and absorbance readings at 510 nm provided the amount of Fe(II) present. Experiments were carried out by alternately circulating solutions of the pharmaceutical under study through channel d at pH 8.5 and an aqueous stream at the same pH. The most favorable results were obtained with adrenaline, chlorpromazine, dipyridamole, pyrimidone, and glycine (Table 1). These pharmaceutical substances were used in further experiments where the reagent (cupric salt) was removed from the reactor in order to ascertain whether the presence of free pharmaceutical substance in the reactor affects the reaction between Fe(III) and thiosulfate. These tests revealed that adrenaline provides the most promising results (under the working conditions used, the pharmaceutical substance was readily oxidized by Fe(III)).

Experiments performed with three amino acids provided results as good as those previously obtained with adrenaline. In fact, the calibration graphs for glycine, histidine, and proline were linear (with correlation coefficients of ca. 0.998) and had similar slopes. The throughput was close to 250 samples h\textsuperscript{-1}.

Notwithstanding the excellence of these results, we tested alternative configurations in order to reduce pharma-
ceu ti cal sub stance con sump tion. In fact, the pre vi ous as -
sem bly re quired a high vol ume of sam ple to flush the
re ac tor on switch ing be tween sam ples of dif fer ent con cen-
tra tions; oth er wise, carry-over would have been quite sig-
nif i cant. In ad di tion, the new ex per i ments were aimed at
in creas ing the sen si tiv ity and de creas ing the de tec tion limit
by di min ish ing the blank sig nal.

A se ries of pre lim i nary ex per i ments were car ried out in
or der to char ac ter ize and con trol the in flu ence of sev eral
ex per i men tal vari ables on the chem i cal sys tem. The in flu-
ence of the re ac tant con cen tra tion was stud ied by keep ing it
con stant in the cir cu lated so lu tions and chang ing the
flow-rate of the streams. The flow-rates of the Fe(III) and
thiosulfate streams (iden ti cal for both) were al ter ed and the
in flu ence of the pres ence of the cat a lyst at vari able con cen-
tra tions of fer ric and thiosulfate ions was stud ied (the
glycine flow-rate was kept con stant and the amino acid was
re placed with wa ter to eval u ate the blank sig nal). The
absorbance de creased with in creas ing flow-rate of the
Fe(III) and thiosulfate streams. The high est absorbances
were ob tained at low flow-rates (lower than 1 mL min
-1)
of
both Fe(III), sul fate and aque ous glycine, which sug gests
that the re dox re ac tion is fa vored by long res i dence times.
How ever, the dif fer ences be tween the sig nals re vealed that
the best re sults were achieved with in ter me di ate cat a-
lyst flow-rates (about 3 mL min
-1)and low Fe(III) and
thiosulfate flow-rates. In other words, a com pro mise must
be made be tween res i dence and con tact times, and an ef fec-
tive cat a lyst con cen tra tion. Ob vi ous ly, the lon ger the res i-
dence time, the greater the ex tent of re ac tion de vel op
da
tion, and hence the greater the de tec tor re sponse. How ever, the
eff ect of in ter fer ences may be in creased. The dif fer ences
be tween the sig nals for the blank (dis tilled wa ter) and the
sam ple (phar ma ceu ti cal sub stance so lu tion) were also il-
lus tra tive of the re ac tion ki net ics in the ab sence of a cat a-
lyst.

We stud ied the de vel op ment of the re ac tion using the
stopped-flow tech nique. For this, we car ried out a se ries of
ex per i ments chang ing the phen con cen tra tion in the pres-
ence and ab sence of the cat a lyst. The flow was stopped for
10 min and 1,10-phenanthroline con cen tra tions in the
range of 0.02-0.5% (w/v) in 0.05 mol L
-1
HCl were cir cu-
lated. In these ex per i ments, the re agent col umn and in jec-
tion valve in Fig. 2 were re moved from the as sem bly, and a
1,10-phenanthroline so lu tion of vari able con cen tra tion
was cir cu lated through chan nel
\(d\).

| Pharmaceutical Substance | Concentration (µg mL
-1) | Absorbance(*) |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycine</td>
<td>5.0</td>
<td>+157.6</td>
</tr>
<tr>
<td>Phenformin</td>
<td>10.5</td>
<td>+10.2</td>
</tr>
<tr>
<td>Penicillin</td>
<td>10.3</td>
<td>+0.4</td>
</tr>
<tr>
<td>Adrenaline</td>
<td>12.4</td>
<td>+248.3</td>
</tr>
<tr>
<td>Terramycine</td>
<td>10.0</td>
<td>+17.9</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>10.8</td>
<td>+17.9</td>
</tr>
<tr>
<td>Metformin</td>
<td>11.3</td>
<td>+16.7</td>
</tr>
<tr>
<td>Ondanestron</td>
<td>10.0</td>
<td>+3.1</td>
</tr>
<tr>
<td>Phenylbarbituric Ac.</td>
<td>11.0</td>
<td>+2.7</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>11.6</td>
<td>+1.4</td>
</tr>
<tr>
<td>Pyramidon</td>
<td>12.2</td>
<td>+59.6</td>
</tr>
<tr>
<td>Captopril</td>
<td>10.7</td>
<td>-9.1</td>
</tr>
<tr>
<td>Dipyrrone</td>
<td>12.0</td>
<td>+45.7</td>
</tr>
<tr>
<td>Ephedrine</td>
<td>10.5</td>
<td>+30.7</td>
</tr>
<tr>
<td>Atropine</td>
<td>11.3</td>
<td>+0.7</td>
</tr>
<tr>
<td>Prometazaine</td>
<td>10.5</td>
<td>+12.2</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>10.0</td>
<td>+10.3</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>10.6</td>
<td>+7.0</td>
</tr>
<tr>
<td>Reserpine</td>
<td>10.1</td>
<td>+6.3</td>
</tr>
<tr>
<td>Procaine HCl</td>
<td>10.0</td>
<td>-0.5</td>
</tr>
<tr>
<td>Moroxydine HU</td>
<td>10.0</td>
<td>+3.0</td>
</tr>
<tr>
<td>Sulfamethoxypyridazine</td>
<td>9.1</td>
<td>+6.3</td>
</tr>
<tr>
<td>Pentobarbital Na</td>
<td>10.1</td>
<td>+8.3</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>9.1</td>
<td>-1.7</td>
</tr>
<tr>
<td>Pyridoxine HCl</td>
<td>12.3</td>
<td>-2.4</td>
</tr>
<tr>
<td>Nicotinamide</td>
<td>10.6</td>
<td>+0.3</td>
</tr>
<tr>
<td>Levamisol HCl</td>
<td>8.9</td>
<td>-3.8</td>
</tr>
<tr>
<td>Folcodine</td>
<td>12.2</td>
<td>-3.5</td>
</tr>
<tr>
<td>Hidroclorotiazide</td>
<td>9.8</td>
<td>-0.7</td>
</tr>
<tr>
<td>Phenylefrine HCl</td>
<td>8.8</td>
<td>-0.3</td>
</tr>
<tr>
<td>Etofomin HCl</td>
<td>10.8</td>
<td>+4.6</td>
</tr>
<tr>
<td>Chloropromazine</td>
<td>10.2</td>
<td>+64.0</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>9.0</td>
<td>+7.7</td>
</tr>
<tr>
<td>Perfenacine</td>
<td>7.6</td>
<td>+4.6</td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>10.3</td>
<td>-2.1</td>
</tr>
<tr>
<td>Pirazinamide</td>
<td>12.9</td>
<td>-2.4</td>
</tr>
<tr>
<td>Pilocarpine HCl</td>
<td>11.0</td>
<td>+1.2</td>
</tr>
</tbody>
</table>

(*) % of absorbance over the blank (analyte solution) absorbance.

ciental substance consumption. In fact, the previous as-
sem bly re quired a high vol ume of sam ple to flush the
reactor on switch ing between samples of different concen-
trations; oth er wise, carry-over would have been quite sig-
nif i cant. In ad di tion, the new ex per i ments were aimed at
in creas ing the sen si tiv ity and de creas ing the de tec tion limit
by di min ish ing the blank sig nal.

A series of preliminary experiments were car ried out in
or der to char ac ter ize and control the in flu ence of several
ex per i men tal vari ables on the chem i cal sys tem. The in flu-
ence of the reactant concentration was studied by keeping it
con stant in the cir cu lated solutions and chang ing the
flow-rate of the streams. The flow-rates of the Fe(III) and
thiosulfate streams (iden ti cal for both) were altered and the
in flu ence of the pres ence of the cat a lyst at variable concen-
tra tions of fer ric and thiosulfate ions was studied (the
glycine flow-rate was kept con stant and the amino acid was
re placed with wa ter to eval u ate the blank sig nal). The
absorbance de creased with in creas ing flow-rate of the
Fe(III) and thiosulfate streams. The high est absorbances
were ob tained at low flow-rates (lower than 1 mL min
-1)of
both Fe(III), sul fate and aque ous glycine, which sug gests
that the re dox re ac tion is fa vored by long res i dence times.
How ever, the dif fer ences be tween the signals re vealed that
the best re sults were achieved with in ter me di ate catalyst
flow-rates (about 3 mL min
-1)and low Fe(III) and
thiosulfate flow-rates. In other words, a com pro mise must
be made be tween res i dence and con tact times, and an ef fec-
tive cat a lyst con cen tra tion. Ob vi ous ly, the lon ger the res i-
dence time, the greater the ex tent of reaction developmen
t, and hence the greater the detector response. How ever, the
eff ect of in ter fer ences may be in creased. The dif fer ences
be tween the signals for the blank (dis tilled wa ter) and the
sam ple (pharma ceu ti cal sub stance so lu tion) were also il-
lus tra tive of the re ac tion ki net ics in the ab sence of a cata-
lyst.

We stud ied the de vel op ment of the re ac tion using the
stopped-flow tech nique. For this, we car ried out a se ries of
ex per i ments chang ing the phen con cen tra tion in the pres-
ence and ab sence of the cat a lyst. The flow was stopped for
10 min and 1,10-phenanthroline con cen tra tions in the
range of 0.02-0.5% (w/v) in 0.05 mol L
-1
HCl were cir cu-
lated. In these ex per i ments, the re agent col umn and in jec-
tion valve in Fig. 2 were re moved from the as sem bly, and a
1,10-phenanthroline so lu tion of variable concentra tion
was cir cu lated through chan nel
\(d\).

There were two ex per i mental batches: one with out a
catalyst and one with a catalyst (using the same as sem bly
but in clud ing Cu(II) con cen tra tions be tween 0 and 3.11 mg
L
-1
in the fer ric solu tion). These ex per i ments al lowed us to
draw the fol low ing con clu sions: (a) the absorbance de-
creased mark edly with de creas ing phen con cen tra tion; (b)
the more con cen trated (0.1, 0.5%) ligand so lu tions gave
much greater slopes in the absorbance vs. time plots; (c) the

table 1. The effects of pharmaceuticals on the release of Cu(II) from
the reactor by displacement reaction.
absorbance increased sharply with an increase in the concentration, both in the presence and absence of a catalyst (absorbance values in the latter case were quite high anyway); (d) a Cu(II) concentration of 3.11 mg L\(^{-1}\) quantitatively converted Fe(III) to Fe(II) ion at time zero; (e) under these conditions, a Cu(II) concentration as low as 6 µg L\(^{-1}\) could be detected.

The influence of other experimental variables was studied using the manifold depicted in Fig. 3. Channel a was used with and without an intercalated solid phase reactor. In the absence of the reactor, the channel was used to circulate Cu(II) at a variable concentration; in its presence, various amino acids at different concentrations were passed. By comparing the signals obtained in both cases, the conversion efficiency of the reactor and the extent of the decomposition of the Cu(II)-amino acid complex were simultaneously determined.

The poor performance of the amino acids in the previous assembly was the likely result of the low quantitiveness of the reaction taking place in the solid phase reactor or of the Cu(II)-amino acid complex being too stable to allow Cu(II) to act as a catalyst. In order to ascertain the reason, the manifold depicted in Fig. 4 was assembled. The Cu(II)-glycine complex was merged with the acidic Fe(III) stream to release Cu(II) by displacement of H\(^{+}\) ion. Two types of transient signals were obtained by circulating a Cu(II) stream through channel a in the absence of the solid phase reactor, and an amino acid stream in the presence of the reactor. The results were similar to the previous ones; however, they allowed us to ascertain that the fact that absorbances could not be higher was not the result of poor mixing (in the previous assembly, three streams converged on the same point), nor of a high stability of the Cu(II)-aminoacid complex. Rather, the sensitivity was limited by the quantitiveness of the reaction between the amino acid and the immobilized cupric salt.

Increased reactor lengths up to 10-15 cm (Fig. 4) resulted in increased signals. The effect of longer lengths was offset by the increased sample dispersion. The peak absorbances obtained at reactor lengths of 10 and 15 cm were 0.138 and 0.139, respectively.

Placing the solid phase reactor in the loop of the injection valve (Fig. 5) was indicated in principle, since it resulted in no sample dispersion during the reaction. In addition, the time the solution and solid bed remained in contact was controlled by switching the valve on and off without the need to stop the flow, which would have required automatic control and detracted from the reproducibility, owing to the typical flow-rate oscillations observed within the first few moments after a peristaltic pump is started. Nevertheless, the many channels included in this manifold caused problems that are usually absent from simpler configurations. Thus, switching the valve on and off caused peak distortions arising from changes in the hydrostatic pressure; the effect varied with column length, which could not be increased at will. The peak for the blank standard could not be minimized. Also, conditioning after the analyte concentration was changed took a fairly long time since the system was not periodically flushed with carrier.

Placing the solid phase reactor between the injection valve and the merging point with ferric solution resulted in a decrease in the blank transient signal; the continuous flow of the carrier solution through the reactor avoids the conditioning or washing steps required in the other manifolds. This manifold was tested by preparing and injecting different concentrations of glycine (up to 8 µg mL\(^{-1}\); five replicates for each point), and resulted in a wider linear graph. This assembly was selected for further work.

The selected manifold (Fig. 1) was optimized in terms of all of the influential chemical and FIA variables involved in the process using the univariate method. The results are summarized in Table 2. The optimization sequence was the same as described in the table, and the experiments involved injecting 280 µL of a 5 µg mL\(^{-1}\) glycine solution.

The selection of the optimum value that could be obtained for each tested parameter was the one which gave the best compromise of peak height-peak base width-rsd (%).
In optimizing the pH, transient signals were corrected for the baseline at pH 11.5, where no signal was observed. Possibly, the lack of a response at pH 11.5 was due to the in situ precipitation of the released Cu(II). The optimal pH, 9.5, was that resulting in the best compromise between the maximum absorbance and the baseline at pH 8.5.

The Fe(III) concentration resulted in a critical variable, and then it was re-optimized with the selected FIA assembly at three different glycine concentrations: 0.5, 1.0, and 2.0 µg mL⁻¹. The Fe(III) concentration range was from 2.0 x 10⁻⁴ to 10.0 x 10⁻⁴ mol L⁻¹. The optimum value, 7.0 x 10⁻⁴ mol L⁻¹, was also relative to the baseline since an increase in the Fe(III) concentration also accelerated the uncatalysed reaction, thereby increasing the blank signal.

Analytical figures of merit

The calibration graph was linear from 0.1 to 3.0 µg mL⁻¹ glycine, and fitted the equation, \( A = -0.0093 + 0.3380 C \), where \( A \) denotes the absorbance and \( C \) the glycine concentration, in micrograms per millilitre. The correlation coefficient was 0.9957. We ran calibration graphs for other a-amino acids, the equations for which are shown in Table 3. A comparison of the slopes of the graphs with those for previously reported methods reveals that the proposed system is 20 times more sensitive in one case and 7 times more in the other; hence, the application range is necessarily short in a spectrophotometric technique with a narrow applicability “window” such as this.

The day-to-day reproducibility was determined by running five calibration graphs for glycine on different days. The average of the slopes obtained was 0.3380, and the relative standard deviation (RSD) was 4.36%. The repeatability of the process was calculated using 16 replicates of an injection of 1 µg mL⁻¹ glycine. The mean peak height and RSD thus obtained were 0.3719 AU and 2.3%, respectively. In the same experiment, the throughput was estimated to be 28 samples h⁻¹.

The influence of foreign substances, some of them accompanying glycine in pharmaceutical formulations, was studied by preparing solutions containing 2.46 µg mL⁻¹ of the amino acid and different concentrations of the potential interferent. Results obtained (relative error in %) were as follows: 0.9 for acetyl acetic acid at 5 µg mL⁻¹; 3.8 for caffeine at 50 µg mL⁻¹, and 5.2 for NaCl at 50 µg mL⁻¹. High errors were calculated for ascorbic and citric acid at 5 µg mL⁻¹, but by preparing concentrations similar to or smaller than that of glycine (which is case of the pharmaceutical formulations) the errors were always smaller than 3%.

Finally, glycine was determined in two different formulations: Okal (tablets, contents according to label claim: acetyl salicylic acid 500 mg, glycine 100 mg and caffeine 30 mg) and Actilevol (ampoules). A few Okal tablets were ground in an agate mortar and an aliquot of ca. 0.35 g of the resulting powder was accurately weighed and dissolved in distilled water. The resulting mixture was filtered and brought to 500 mL with distilled water; ten milliliters of the resulting solution were leveled to 100 mL; aliquots of 5 mL were adjusted to pH 3 with 0.1 mol L⁻¹ HCl and the acetyl salicylic acid was removed by extraction with diethyl ether.

The second formulation, Actilevol (ampoules, composition according to label claim: ascorbic acid 500 mg, hemathoporphyrin 6 mg, glycine 500 mg, concentrated live extract 20 mg, id yeast 100 mg, sodium citrate 300 mg, ethanol 0.05 g) was processed by diluting an ampoule to 10 mL with distilled water. This stock solution was used to prepare several dilutions from 10% to 20% (w/v). The re-

---

Table 2. The range of optimized variables and selected values.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Tested Range</th>
<th>Selected Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,10-phenanthroline (%)(w/v)</td>
<td>0.10-1.00</td>
<td>0.5</td>
</tr>
<tr>
<td>pH carrier</td>
<td>6.0-11.5</td>
<td>9.5</td>
</tr>
<tr>
<td>Na₂SO₃ (g L⁻¹)</td>
<td>1.40-7.40</td>
<td>6.40</td>
</tr>
<tr>
<td>Fe(III) (mol L⁻¹)</td>
<td>(2.0-10.0) x 10⁻⁴</td>
<td>7.0 x 10⁻⁴</td>
</tr>
<tr>
<td>Coil reactor length (L₃)(cm)</td>
<td>32-202</td>
<td>112</td>
</tr>
<tr>
<td>Coil reactor length (L₂)(cm)</td>
<td>90-570</td>
<td>480</td>
</tr>
<tr>
<td>Coil reactor length (L₁)(cm)</td>
<td>10-280</td>
<td>10</td>
</tr>
<tr>
<td>Sample volume (µL)</td>
<td>90-729</td>
<td>578</td>
</tr>
<tr>
<td>Solid-phase reactor length (cm)</td>
<td>5-25</td>
<td>10</td>
</tr>
</tbody>
</table>

---

Table 3. Calibration equations with the optimal flow-injection assembly for different a-amino acids.

<table>
<thead>
<tr>
<th>Amino Acid</th>
<th>Equation (c in µg mL⁻¹)</th>
<th>Corr. Coeff.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine</td>
<td>y = 0.0196 + 0.2633 c</td>
<td>0.9936</td>
</tr>
<tr>
<td>Proline</td>
<td>y = 0.0170 + 0.1589 c</td>
<td>0.9952</td>
</tr>
<tr>
<td>Cysteine</td>
<td>y = -0.0868 + 0.2608 c</td>
<td>0.9993</td>
</tr>
<tr>
<td>Histidine</td>
<td>y = -0.0567 + 0.1492 c</td>
<td>0.9943</td>
</tr>
</tbody>
</table>
The results obtained were quite consistent with the certified values, namely: 102.5 mg/tablet for Okal (certified content 100 mg/tablet, relative error 2.5%) and 507.9 mg/ampoule (certified content 500 mg/ampoule, relative error 1.6%). The results obtained were compared with those obtained with a reference method\textsuperscript{16}, in which the determination of glycine was carried out by AAS using the same solid-phase reactor without a derivation reaction. The results obtained were: Okal (99.85 mg/tablet) and Actilevol (497.1 mg/ampoule).

**Conclusions**

The proposed FIA configuration uses a solid phase reactor that provides a dilute, reproducible stream of constant concentration that acts as a catalyst in a subsequent reaction. The product of such a reaction is used to indirectly obtain the concentration of the species released by the metal ion acting as the catalyst.

The proposed method allows monitoring procedures for organic compounds based on atomic absorption measurements (of the released metal ion) to be converted into molecular absorption procedures, which are much more commonplace in pharmaceutical analysis. In addition, the use of a catalytic procedure is a possible way to improve the detection limits and sensitivity of the method.

**References**